Cas No.: | 202821-81-6 |
Chemical Name: | 3-[(5-chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl]-1,3,4-oxadiazol-2(3H)-one |
Synonyms: | BMS-191011; BMS 191011; BMS191011; UNII-LW7MXS978N; Bms-a. |
SMILES: | O=C1OC(C2=CC=C(C(F)(F)F)C=C2)=NN1CC3=C(O)C=CC(Cl)=C3 |
Formula: | C16H10ClF3N2O3 |
M.Wt: | 370.71 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | BMS-191011 (BMS-A) is an opener of the large-conductance, Ca2++-activated potassium (maxi-K) channel, effective in stroke models[1]. |
References: | [1]. Romine JL, et al. 3-[(5-Chloro-2-hydroxyphenyl)methyl]-5-[4-(trifluoromethyl)phenyl ]-1,3,4-oxadiazol-2(3H)-one, BMS-191011: opener of large-conductance Ca(2+)-activated potassium (maxi-K) channels, identification, solubility, and SAR. J Med Chem. 2007 Feb 8;50(3):528-42. |